Loading
A phase 2 trial of UGT1A1 genotyping before irinotecan in Colorectal cancer, run by Federation Francophone de Cancerologie Digestive, completed.
G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer is a phase 2 interventional study registered as NCT00541125 by Federation Francophone de Cancerologie Digestive, with 20 participants recorded, started 2007-11 and reaching its primary completion in 2013-09. Interventions recorded: bevacizumab, filgrastim, fluorouracil, irinotecan hydrochloride, leucovorin calcium. Conditions recorded: Colorectal Cancer.
Linked to the technology UGT1A1 genotyping before irinotecan because the registry's title names it ("ugt1a1 28") and Colorectal cancer among its conditions. Registry record only: no result has been read by an editor.
Shares UGT1A1, UGT1A1 genotyping before irinotecan, Irinotecan (and liposomal irinotecan), Leucovorin (folinic acid) and the tag pipeline.
Shares UGT1A1, UGT1A1 genotyping before irinotecan, Irinotecan (and liposomal irinotecan), Colorectal cancer and the tag pipeline.
Shares Irinotecan (and liposomal irinotecan), Leucovorin (folinic acid), Fluorouracil (5-FU), Colorectal cancer and the tag pipeline.
Shares Irinotecan (and liposomal irinotecan), Leucovorin (folinic acid), Fluorouracil (5-FU), Colorectal cancer and the tag pipeline.
Shares Irinotecan (and liposomal irinotecan), Fluorouracil (5-FU), Colorectal cancer and the tag pipeline.
Shares Leucovorin (folinic acid), Fluorouracil (5-FU), Colorectal cancer and the tag pipeline.
Shares Leucovorin (folinic acid), Fluorouracil (5-FU), Colorectal cancer and the tag pipeline.
Shares Leucovorin (folinic acid), Colorectal cancer and the tag pipeline.